eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026
Rhea-AI Summary
eXoZymes (NASDAQ:EXOZ) will host a webinar on Tuesday, March 31, 2026 at 5:30 PM ET to review fourth quarter and full year 2025 results. CEO Michael Heltzen and select management will discuss recent developments, ongoing initiatives, anticipated milestones, and hold a Q&A.
A press release with results will be issued prior to the call. Investors can pre-register and access the live webinar via the company’s investor relations site at https://exozymes.com/investor.
Positive
- None.
Negative
- None.
News Market Reaction – EXOZ
In the Mar 26 session, EXOZ gained 0.42%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Earnings call webinar | Neutral | +13.7% | Announcement of Q1 2025 results webinar and NCTx business update. |
| Mar 26 | Year-end call notice | Neutral | -19.7% | Scheduling fourth quarter and full year 2024 financial results webinar. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past earnings/webinar announcements produced volatile and directionally mixed reactions, with one strong gain and one sharp selloff.
Recent tag-matched history for EXOZ shows two prior conferences,earnings announcements. On May 7, 2025, a first quarter 2025 results and NCTx update webinar notice preceded a 13.73% move. On March 26, 2025, a fourth quarter and full year 2024 call announcement saw a -19.67% reaction. The average move of -2.97% underscores that seemingly routine scheduling releases have coincided with sizable price swings.
Key Terms
feedstock technical
nutraceuticals medical
webinar technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
LOS ANGELES, CA / ACCESS Newswire / March 25, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Tuesday, March 31, 2026 at 5:30 PM Eastern Time to discuss its results for the fourth quarter and full year 2025. A press release detailing these results will be issued prior to the call.
CEO of eXoZymes, Michael Heltzen, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period.
Investors can pre-register for the webinar HERE.
On the day of the event, the live webinar can also be accessed through eXoZymes' investor relations website at https://exozymes.com/investor.
About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce highly valuable natural products, via a commercially scalable, sustainable, and abundant alternative: exozymes.
Exozymes are advanced enzymes enhanced through bioengineering and AI to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform abundant feedstock into valuable nutraceuticals and novel medicines.
By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.
While the company, eXoZymes Inc., has introduced "exozymes" as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.
Learn more at exozymes.com.
eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.
eXoZymes contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com
https://www.linkedin.com/company/exozymes
https://x.com/exozymes
https://www.youtube.com/@exozymes
SOURCE: eXoZymes
View the original press release on ACCESS Newswire